{"id":89553,"title":"Omega Diagnostics Gp (ODX.L) Update on CTDA Regulations","publisher":"Share Talk","author":"sharetalk","published":"2021-11-03T07:56:17+00:00","modified":"2021-11-03T07:56:17+00:00","canonical_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-update-on-ctda-regulations/","markdown_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-update-on-ctda-regulations.md","json_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-update-on-ctda-regulations.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["Abingdon Health","Administration","Antigen Test","china","Colin King","Contract","COVID-19","David Grouse","diagnostic","diseases","Drug","Food","infectious","Manufacturing","Medical","Mologic Ltd","ODX","Omega Diagnostics","Omega Diagnostics Gp","Rapid Test","scientists","Screen4","UK Government","UK-RTC","University of Oxford"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Omega (AIM: ODX)**, the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, notes the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”) which were implemented on 1 November 2021.\n\nThe new CTDA Regulations required all suppliers of COVID-19 tests to submit information regarding their products for desktop review prior to 31 October 2021 if they wished their products to remain on sale in the UK after this date. This is a new requirement over and above the requirement for the CE Mark secured for Omega’s VISITECT® professional-use COVID-19 Antigen test (“LFT”) earlier this year.\n\nOmega submitted all documentation ahead of the published deadlines and paid the necessary fee, however, in line with the vast majority of available tests on the market Omega’s existing LFT has yet to be approved under CTDA.\n\nThis new legislation is not expected to cause a delay in the supply of Omega’s VISITECT® professional-use COVID-19 Antigen test to DAM Health clinics in the UK under the agreement announced on 1 November 2021. Omega currently remains free to supply LFTs to DAM Health’s clinics throughout Europe and DAM Health are able to distribute Omega’s LFT throughout Europe\n\nThe Company will update shareholders as soon as they receive a further update from the UK Health Security Agency.\n\n**Contacts:**\n\n**Omega Diagnostics Group PLC**\n\n[www.omegadx.com](http://www.omegadx.com)\n\n**Colin King, Chief Executive**\n\n**via Walbrook PR**\n\n**Chris Lea, Chief Financial Officer**\n\nAbout Omega Diagnostics Group PLC\n\nOmega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health."}